Treatment
Bendamustine clinical trials
We’re tracking 41 recruiting studies that include Bendamustine, each written for real people, not researchers, below.
Recruiting studies
- NCT06911502RecruitingPhase 3
Golcadomide plus rituximab for relapsed follicular lymphoma
This trial tests a new drug, Golcadomide, combined with rituximab, for people with follicular lymphoma that has come back or hasn't responded to prior treatment. The goal is to see if this combination works better than other treatments your doctor might choose.
Birmingham, AlabamaAges 18 years+ - NCT06846671RecruitingPhase 3
Study of a new drug for CLL or SLL
This trial tests a new investigational drug, BGB-16673, for people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have already tried two types of treatments (BTK and BCL2 inhibitors). The goal is to see if this new drug works better than other available treatments chosen by the doctor.
Jonesboro, ArkansasAges 18 years+ - NCT06504940RecruitingPhase 2
Study of orelabrutinib plus BR or G for untreated marginal zone lymphoma
This trial tests a combination of targeted therapy (orelabrutinib) plus chemotherapy (BR) or antibody therapy (G) for people with untreated marginal zone lymphoma. It aims to see if this combination can help patients who haven't had treatment yet.
Hangzhou, ZhejiangAges 18 years+ - NCT06483048RecruitingPhase 1
MUC1-targeted T cells for relapsed ovarian cancer
This trial tests a new treatment using your own immune cells, modified to target a protein called MUC1 on ovarian cancer cells. It is for people with ovarian cancer that has come back or is resistant to standard treatments.
Scottsdale, ArizonaAges 18 years+ - NCT06308978RecruitingPhase 1
Study of FT819 for B-cell autoimmune diseases
This trial tests a new cell therapy, FT819, for people with certain autoimmune diseases like lupus, vasculitis, myositis, or scleroderma that haven't improved with at least two previous treatments. The goal is to see if it can help control the disease.
Beverly Hills, CaliforniaAges 12–70 - NCT06241456RecruitingPhase 1
Experimental CAR-T cells targeting HER2 for advanced solid tumors
This trial tests an experimental 'off-the-shelf' CAR-T cell therapy (called FT825/ONO-8250) that targets a protein called HER2 found on some solid tumors. It may be given alone or with other antibodies to help fight advanced cancer that has not responded to standard treatments.
Gilbert, ArizonaAges 18 years+ - NCT06191887RecruitingPhase 1
BAFFR-targeting CAR-T cells for relapsed B-cell blood cancers
This trial tests a new type of immune cell therapy (CAR-T cells) that targets a protein called BAFFR on B-cell blood cancers. The goal is to see if it can shrink tumors when given after a short chemotherapy course to prepare the body.
Jacksonville, FloridaAges 18 years+ - NCT06084936RecruitingPhase 3
Glofitamab alone vs other treatments for mantle cell lymphoma
This trial tests a new drug called glofitamab to see if it works better than other standard treatments for people with mantle cell lymphoma that has come back or not responded to previous therapy. It is for patients who have already tried a BTK inhibitor and at least one other treatment.
Berkeley, CaliforniaAges 18 years+ - NCT06091254RecruitingPhase 3
Comparing odronextamab to standard chemo for untreated follicular lymphoma
This trial tests if a new drug called odronextamab is safe and works as well as a common antibody (rituximab) plus chemotherapy for people with a type of slow-growing lymphoma that hasn't been treated yet. It's for adults with grade 1-3a follicular lymphoma that is bulky stage II or stage III/IV.
Tucson, ArizonaAges 18 years+ - NCT06043713RecruitingPhase 1
T-cell therapy for KRAS G12V solid tumors
This trial tests a personalized T-cell therapy designed to recognize and attack cancer cells with a specific KRAS G12V mutation. It is for people with metastatic solid tumors that have this mutation and a specific immune type (HLA-A*11:01).
Seattle, WashingtonAges 18 years+ - NCT06006117RecruitingPhase 3
Testing a new drug combination for relapsed marginal zone lymphoma
This trial compares a combination of mosunetuzumab and lenalidomide against standard treatments for people with marginal zone lymphoma that has come back or stopped responding to previous therapy. It aims to find out if the new combination works better than current options.
AnderlechtAges 18 years+ - NCT05848765RecruitingPhase 2
Trial for relapsed follicular lymphoma after prior chemo
This Phase 2 trial studies treatment options for follicular lymphoma that has returned or did not respond to prior therapy. It compares a standard chemotherapy approach against another study treatment to see which works better and is tolerable.
AberdeenAges 18 years+ - NCT05139017RecruitingPhase 2/Phase 3
Test drug Zilovertamab vedotin with standard care for lymphoma
This trial studies zilovertamab vedotin added to standard chemotherapy for people with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). It may help by targeting lymphoma cells and improving how well standard treatment works after prior treatments have failed.
Glendale, ArizonaAges 18 years+ - NCT04892277RecruitingPhase 1
CD19 CAR-T for adults with hard-to-treat B-cell cancers
This Phase 1 trial tests a lab-made immune therapy (CD19 CAR-T) for adults whose B-cell cancers have come back or did not respond to treatment. It may help your immune system better recognize and attack cancer cells, but it is early research, so benefits and risks are still being defined.
Rochester, MinnesotaAges 18 years+ - NCT04792489RecruitingPhase 2
CAR-T cell therapy for aggressive B-cell lymphomas
This trial tests a new CAR-T cell treatment (MB-CART2019.1) for people with certain types of aggressive B-cell non-Hodgkin lymphoma, including diffuse large B-cell lymphoma (DLBCL) that has come back or not responded to prior treatments. It aims to see if this therapy can help when other options have failed.
Birmingham, AlabamaAges 18 years+ - NCT04223765RecruitingPhase 1
Testing a new CAR T-cell treatment for kappa cancers
This Phase 1 trial studies a lab-made immune therapy (CAR T cells) that targets “kappa” markers on certain lymphomas and CLL/SLL. It’s for people whose cancer has come back or didn’t respond to standard treatments, aiming to improve control of the disease.
Chapel Hill, North CarolinaAges 18 years+ - NCT04083495RecruitingPhase 2
CAR T treatment for relapsed CD30-positive T-cell lymphoma
This trial tests a lab-made immune therapy (CAR T cells) for lymphoma that has come back or did not respond to treatment, specifically CD30-positive T-cell lymphoma. The goal is to shrink the cancer and help keep it under control after previous therapies, including people who have relapsed after stem cell transplant.
Chapel Hill, North CarolinaAges 18–99
Common questions
- Are there clinical trials studying Bendamustine?
- Yes. Clin2 currently lists 41 recruiting studies that include Bendamustine, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Bendamustine trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Bendamustine an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Bendamustine or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.